Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Blood Advances Année : 2019

Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance

Karim Maloum
  • Fonction : Auteur
  • PersonId : 882079

Résumé

Chronic lymphocytic leukemia (CLL), the most common adulthood leukemia in Western countries, is a very heterogeneous disease characterized by a peripheral accumulation of abnormal CD5+ B lymphocytes in the immune system. Despite new therapeutic developments, there remains an unmet medical need for CLL. Here, we demonstrate that the use of N-methylated thrombospondin-1 (TSP-1)-derived peptides is an efficient way to kill the malignant CLL cells, including those from high-risk individuals with poor clinical prognosis, del11q, del17p, 2p gain, or complex karyotype. PKT16, our hit N-methylated peptide, triggers the elimination of the leukemic cells, sparing the nontumor cells, including the hematopoietic precursors, and reduces the in vivo tumor burden of a CLL-xenograft mice model. A complementary analysis underscores the improved cytotoxic efficiency of PKT16 compared with the previously described TSP-1-derived probes, such as PKHB1. PKT16 elicits an original caspase-independent programmed necrotic mode of cell death, different from necroptosis or ferroptosis, implicating an intracellular Ca2+ deregulation that provokes mitochondrial damage, cell cycle arrest, and the specific death of the malignant CLL cells. The activation of the Gαi proteins and the subsequent drop of cyclic adenosine monophosphate levels and protein kinase A activity regulate this cytotoxic cascade. Remarkably, PKT16 induces the molecular hallmarks of immunogenic cell death, as defined by the calreticulin plasma membrane exposure and the release of adenosine triphosphate and high-mobility group box 1 protein from the dying CLL cells. Thus, PKT16 appears to be able to stimulate an anticancer in vivo immune response. Collectively, our results pave the way toward the development of an efficient strategy against CLL.
Fichier principal
Vignette du fichier
Pramil et al 2019 text.pdf (211.54 Ko) Télécharger le fichier
Pramil et al 2019 Figures.pdf (8.13 Mo) Télécharger le fichier
Supplementary Information Pramil et al. 2019.pdf (2.79 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02363823 , version 1 (14-11-2019)

Identifiants

Citer

Elodie Pramil, Linda Herbi Bastian, Thomas Denèfle, Fariba Nemati, Malina Xiao, et al.. Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance. Blood Advances, 2019, 3 (20), pp.2920-2933. ⟨10.1182/bloodadvances.2019000350⟩. ⟨hal-02363823⟩
107 Consultations
102 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More